Who founded Neonc Technologies Holdings?

Neonc Technologies Holdings was founded by Thomas Chen, MD, PhD in 2023.

How much funding has Neonc Technologies Holdings raised?

Neonc Technologies Holdings has disclosed $126.6M raised across 7 rounds.

Where is Neonc Technologies Holdings headquartered?

Neonc Technologies Holdings is headquartered in Westlake Village, US.

Neonc Technologies Holdings

NASDAQ: NTHI

Westlake Village, US · Founded 2023 · Delaware corporation

Find your way into Neonc Technologies Holdings

Paths you didn't know you had: your email and LinkedIn already hold routes to the Neonc Technologies Holdings team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

NeOnc is a biopharmaceutical company developing a patented platform technology to transport therapeutics across the blood-brain barrier, including intranasal delivery formulations such as NEO100 and NEO400. It targets brain and central nervous system diseases like glioblastoma and other brain cancers, serving patients and partnering with pharmaceutical companies.

Biotech Healthtech Medical Devices

Founders & leadership

Neonc Technologies Holdings was founded in 2023 by Thomas Chen, MD, PhD.

Thomas Chen, MD, PhDCEO, CSO, Founder, NeOnc Technologies Inc.

PATRICK WALTERS ExecutivePatrick Walters served as CFO/COO at NeOnc Technologies, leading financial and operational infrastructure through IPO preparation, securing over $40M in capital and licensing deals. Previously, he held finance leadership roles at Modern Luxury Media and Sony Pictures Entertainment, and began his career at Deloitte & Touche.

Amir Heshmatpour Executive ChairAmir Heshmatpour is Executive Chairman of NeOnc Technologies, a biopharmaceutical company developing a blood-brain barrier transport platform for CNS diseases. He brings over 20 years of private equity and executive management experience, including prior work as Managing Director at AFH Holding & Advisory.

Keithly Garnett Chief Financial OfficerChief Financial Officer of NeOnc Technologies Holdings, a biopharmaceutical company developing blood-brain barrier transport technology for CNS diseases. Garnett brings over twenty-five years of experience in financial analysis, accounting, treasury, and transaction advisory, including work with Fortune 500 companies and counsel on public company filings and disclosures.

David Suh Chief Accounting OfficerDavid Suh is Chief Accounting Officer at NeOnc Technologies Holdings, a biopharmaceutical company developing blood-brain barrier transport technology for CNS diseases. He brings 10 years of experience in controllership, financial compliance, and accounting processes across multiple organizations.

Josh Neman Chief Clinical OfficerJosh Neman is an Associate Professor of Neurological Surgery and Physiology & Neuroscience at USC's Keck School of Medicine, where he directs the Cancer Biology & Genomics PhD Program and serves as Scientific Director of the USC Brain Tumor Center. He holds a PhD in Neurobiology from UCLA and completed a cancer biology fellowship at City of Hope, with research focused on cancer neuroscience, brain metastases, and pediatric brain tumors.

ALAN CHIANGNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$126.6M disclosed across 7 rounds · 2023–2026

▶$5MraisedJun 2026 · 2 investors · Biotechnology

Rule 506(b)